Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mach7 Technologies ( (AU:M7T) ) has shared an update.
Mach7 Technologies Limited announced that Mike Lampron has ceased to be a director as of June 30, 2025. Despite his departure, Lampron retains a portion of his performance rights based on his service period as CEO and Managing Director, retaining 1,189,667 rights while forfeiting 1,033,333 rights. This change in leadership may impact the company’s strategic direction and operational focus, potentially affecting its market positioning and stakeholder interests.
The most recent analyst rating on (AU:M7T) stock is a Buy with a A$0.95 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
More about Mach7 Technologies
Mach7 Technologies Limited operates in the technology industry, focusing on providing innovative solutions for healthcare data management and imaging. The company specializes in developing software for medical imaging and enterprise data management, catering primarily to the healthcare sector.
Average Trading Volume: 271,630
Technical Sentiment Signal: Sell
Current Market Cap: A$83.23M
Learn more about M7T stock on TipRanks’ Stock Analysis page.